 Home > Active Ingredient News > Antitumor Therapy > ASCO 2021: data from monarchE Chinese population: Abesiride combined with endocrine therapy for early breast cancer reduces the risk of recurrence by 34%

ASCO 2021: data from monarchE Chinese population: Abesiride combined with endocrine therapy for early breast cancer reduces the risk of recurrence by 34%

 Last Update: 2021-06-16
 Source: Internet
 Author: User

Tags

cancer

artemisinin cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The 2021 American Society of Clinical Oncology (ASCO) Annual Meeting will be held on June 4-8, 2021 Eastern Time

This article is from Yimaitong authorized to reprint

this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gefitinib

CAS No.: 184475-35-2

Pharmacy Grade

$1/MT FOB

High quality Sunitinib CAS NO 557795-19-4 Orange solid powder 99% API for antitumor

CAS No.: 557795-19-4

Pharmacy Grade

$4.1-4.2/G FOB

Epirubicin

CAS No.: 56420-45-2

$1/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.